LLY · 8-K · 20260805PR000077

Product Launch - Foundayo

ELI LILLY & Co · 2026-08-05 · Importance 34 · Surprise 42

Foundayo, Lilly's oral GLP-1 orforglipron, generated $98 million of Q2 2026 revenue after being added to Key Products. Lilly reported that Foundayo delivered superior A1C control and weight loss in three pivotal type 2 diabetes trials. The company also stated that Foundayo was associated with significant weight loss in women at every stage of menopause and can be taken without food or water restrictions. Foundayo and Zepbound were reported as covered for millions of Americans.

Key facts